Literature DB >> 23242575

Evolving changes in the management of early oesophageal adenocarcinoma in a tertiary centre.

N J O'Farrell1, J V Reynolds, N Ravi, J O Larkin, V Malik, G F Wilson, C Muldoon, D O'Toole.   

Abstract

OBJECTIVES: Series from high volume oesophageal centres highlight an increasing prevalence of early malignant (EM) lesions. The advent of endoscopic mucosal resection (EMR) and radiofrequency ablation (RFA) offer alternatives to traditional surgery. The evolution of this pattern of care in a high volume centre is analysed.
METHODS: Data were collected from a prospectively maintained database. 96 patients were treated with an EM lesion from 2000 to 2011. Surgery was the standard approach during the initial period (2000-2006). In 2007, with the introduction of EMR±RFA to our Centre, a rising trend toward definitive endoscopic treatment was seen. This study details the selection of cases into treatment groups and their outcomes.
RESULTS: From 2000 to 2006, 23 patients were treated with EM lesions, 96% by surgery. Seventy-three were treated from 2007 to 2011, 55% surgically and 45% by EMR±RFA. In the entire experience, there was one death from surgery and morbidity was higher in the surgery group compared with EMR±RFA (p<0.001). Three surgical patients (4.8%) relapsed with HGD or cancer, and one patient with T1N1 disease died of disease recurrence. At a median of 13 months, EMR±RFA offered 100% disease control, 72% had no endoscopic or histological evidence of Barrett's oesophagus and one patient represented with low grade dysplasia.
CONCLUSIONS: This study highlights the changing pattern of care in the management of early oesophageal cancer. EMR±RFA appears an acceptable alternative to surgery in carefully selected cases. However, long-term outcome analysis using these methods is required and close interdisciplinary collaboration of specialists in gastroenterology, surgery, pathology and radiology is mandatory to achieve optimum outcomes.

Entities:  

Mesh:

Year:  2012        PMID: 23242575     DOI: 10.1007/s11845-012-0890-x

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  36 in total

1.  Gastro-oesophageal cancer: death at the junction.

Authors:  J A Jankowski; I Perry; R F Harrison
Journal:  BMJ       Date:  2000 Aug 19-26

2.  Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus.

Authors:  C Ell; A May; L Gossner; O Pech; E Günter; G Mayer; R Henrich; M Vieth; H Müller; G Seitz; M Stolte
Journal:  Gastroenterology       Date:  2000-04       Impact factor: 22.682

3.  Prospective evaluation of quality of life in patients with localized oesophageal cancer treated by multimodality therapy or surgery alone.

Authors:  J V Reynolds; R McLaughlin; J Moore; S Rowley; N Ravi; P J Byrne
Journal:  Br J Surg       Date:  2006-09       Impact factor: 6.939

4.  Superficial adenocarcinoma of the esophagus.

Authors:  T W Rice; E H Blackstone; J R Goldblum; M M DeCamp; S C Murthy; G W Falk; A H Ormsby; L A Rybicki; J E Richter; D J Adelstein
Journal:  J Thorac Cardiovasc Surg       Date:  2001-12       Impact factor: 5.209

5.  Length of Barrett's segment predicts success of extensive endomucosal resection for eradication of Barrett's esophagus with early neoplasia.

Authors:  T Thomas; L Ayaru; E Y Lee; M Cirocco; G Kandel; G May; P Kortan; N E Marcon
Journal:  Surg Endosc       Date:  2011-08-20       Impact factor: 4.584

6.  Clinical biology and surgical therapy of intramucosal adenocarcinoma of the esophagus.

Authors:  Daniel S Oh; Jeffrey A Hagen; Parakrama T Chandrasoma; Christy M Dunst; Steven R Demeester; Mohammad Alavi; Cedric G Bremner; John Lipham; Christian Rizzetto; Richard Cote; Tom R Demeester
Journal:  J Am Coll Surg       Date:  2006-06-22       Impact factor: 6.113

7.  Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer.

Authors:  John Vincent Reynolds; Cian Muldoon; Donal Hollywood; Narayanasamy Ravi; Suzanne Rowley; Ken O'Byrne; John Kennedy; Thomas J Murphy
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

8.  Eradication of Barrett esophagus with early neoplasia by radiofrequency ablation, with or without endoscopic resection.

Authors:  Roos E Pouw; Joep J Gondrie; Carine M Sondermeijer; Fiebo J ten Kate; Thomas M van Gulik; Kausilia K Krishnadath; Paul Fockens; Bas L Weusten; Jacques J Bergman
Journal:  J Gastrointest Surg       Date:  2008-08-13       Impact factor: 3.452

9.  Mortality rates in patients with Barrett's oesophagus.

Authors:  P Moayyedi; N Burch; N Akhtar-Danesh; S K Enaganti; R Harrison; N J Talley; J Jankowski
Journal:  Aliment Pharmacol Ther       Date:  2007-12-06       Impact factor: 8.171

10.  Esophagectomy for T1 esophageal cancer: outcomes in 100 patients and implications for endoscopic therapy.

Authors:  Arjun Pennathur; Andrew Farkas; Alyssa M Krasinskas; Peter F Ferson; William E Gooding; Michael K Gibson; Matthew J Schuchert; Rodney J Landreneau; James D Luketich
Journal:  Ann Thorac Surg       Date:  2009-04       Impact factor: 4.330

View more
  2 in total

1.  Endoscopic mucosal resection for staging and treatment of early esophageal carcinoma: a single institution experience.

Authors:  Justin T Huntington; Jon P Walker; Michael P Meara; Jeffrey W Hazey; W Scott Melvin; Kyle A Perry
Journal:  Surg Endosc       Date:  2014-12-04       Impact factor: 4.584

2.  Impact of the development of an endoscopic eradication program for Barrett's esophagus with high grade dysplasia or early adenocarcinoma on the frequency of surgery.

Authors:  Prianka Chilukuri; Mark A Gromski; Cynthia S Johnson; Duy Khanh P Ceppa; Kenneth A Kesler; Thomas J Birdas; Karen M Rieger; Hala Fatima; William R Kessler; Douglas K Rex; Mohammad Al-Haddad; John M DeWitt
Journal:  Endosc Int Open       Date:  2018-09-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.